DashboardPortfoliosWatchlistCommunityDiscoverScreener
NOT FOR DISTRIBUTION
Loading...
  • Stocks
  • /
  • Healthcare
Updated 1m ago
ACBM logo

Acro Biomedical Co., Ltd.OTCPK:ACBM Stock Report

Market Cap US$1.6m
Updated 1m ago
Share Price
n/a
1Yn/a
7D0%
Portfolio Value
​
View

Acro Biomedical Co., Ltd.

OTCPK:ACBM Stock Report

Market Cap: US$1.6m

  • Company Overview
  • Valuation
  • Future Growth
  • Past Performance
  • Financial Health
  • Dividend
  • Management
  • Ownership
  • Other Information
  • Stock Community

Acro Biomedical (ACBM) Stock Overview

Engages in the development and marketing of nutritional products in Indiana and internationally. More details

ACBM fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Risk Analysis

Does not have a meaningful market cap ($2M)

Makes less than USD$1m in revenue ($0)

Has less than 1 year of cash runway

Shares are highly illiquid

+ 1 more risk

ACBM Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW436,653 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
436,653 investors already sharing narratives
US$
Current Price
US$0.026n/aintrinsic discount
Est. Revenue
$
PastFuture-15m6m2016201920222025202620282031Revenue US$0.004Earnings US$0.0003
Advanced
View all narratives

Acro Biomedical Co., Ltd. Competitors

Virax Biolabs Group

Symbol: NasdaqCM:VRAX
Market cap: US$2.1m

Agape ATP

Symbol: NasdaqCM:ATPC
Market cap: US$2.3m

Aethlon Medical

Symbol: NasdaqCM:AEMD
Market cap: US$1.3m

PD-Rx Pharmaceuticals

Symbol: OTCPK:PDRX
Market cap: US$5.1m

Price History & Performance

Summary of share price highs, lows and changes for Acro Biomedical
Historical stock prices
Current Share PriceUS$0.026
52 Week HighUS$0.10
52 Week LowUS$0.022
Beta-2.38
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Change-98.27%
5 Year Change-99.48%
Change since IPO-98.96%

Recent News & Updates

Recent updates

Shareholder Returns

ACBMUS HealthcareUS Market
7D0%-1.6%-0.2%
1Yn/a18.2%14.8%

Return vs Industry: Insufficient data to determine how ACBM performed against the US Healthcare industry.

Return vs Market: Insufficient data to determine how ACBM performed against the US Market.

Price Volatility

Is ACBM's price volatile compared to industry and market?
ACBM volatility
ACBM Average Weekly Movementn/a
Healthcare Industry Average Movement7.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.9%

Stable Share Price: ACBM's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine ACBM's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2014n/aNick Chenacrobiomedicalco.com

Acro Biomedical Co., Ltd. engages in the development and marketing of nutritional products in Indiana and internationally. It is involved in the development and sale of cordyceps related products, a fungus used in traditional Chinese medicine. The company was formerly known as Killer Waves Hawaii, Inc. and changed its name to Acro Biomedical Co., Ltd.

Acro Biomedical Co., Ltd. Fundamentals Summary

How do Acro Biomedical's earnings and revenue compare to its market cap?
ACBM fundamental statistics
Market capUS$1.56m
Earnings (TTM)-US$140.41k
Revenue (TTM)n/a
0.0x
P/S Ratio
-11.1x
P/E Ratio

Is ACBM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ACBM income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$140.41k
Earnings-US$140.41k

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-0.0023
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio-86.6%

How did ACBM perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/10 19:52
End of Day Share Price 2026/06/16 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
  • SEC Form 10-K
  • SEC Form 10-Q
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
  • Analyst Research Reports
  • Blue Matrix
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
  • ICE Market Data
  • SEC Form S-1
Ownership10 years
  • Top shareholders
  • Insider trading
  • SEC Form 4
  • SEC Form 13D
Management10 years
  • Leadership team
  • Board of directors
  • SEC Form 10-K
  • SEC Form DEF 14A
Key Developments10 years
  • Company announcements
  • SEC Form 8-K

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Acro Biomedical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide